Implementation of penicillin allergy de-labelling calls for an understanding of the key barriers and enablers in healthcare systems – topics that the iNAAN and ALABAMA studies address, explains… read more.
The PALACE study showed that in people at low-risk of penicillin allergy, a direct oral challenge with penicillin was no less effective than standard allergy testing for determining… read more.
Neil Powell combines the roles of a consultant antimicrobial pharmacist and a clinical researcher at the Royal Cornwall Hospital in Truro. His current research is focused on the… read more.
Prepared infusions of nanoparticle albumin-bound (nab) paclitaxel are stable for seven days, when stored in a refrigerator, according to researcher Helen Linxweiler (University Medical Centre of Johannes Gutenberg… read more.
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.
The pilot study of pharmacist-led vitamin D point-of-care testing showed that the procedure was feasible in routine practice and, surprisingly, that more than half of participants had insufficient… read more.
Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
